GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN –– Approval based on positive data ...
The Food and Drug Administration (FDA) approved a new drug to treat a disorder causing the growth of non-cancerous tumors on ...
Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...
The drug offers a non-addictive alternative to opioids, marking 'an important public health milestone in acute pain ...
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...
today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for the Company’s groundbreaking 12-lead electrocardiogram (ECG) synthesis software designed ...
--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted ... granted upon product approval. This important regulatory ...
C&EN’s tabulation follows approvals from the FDA’s Center for Drug Evaluation and Research; therefore, it does not include blood products, gene therapies, vaccines, and other therapies that ...
The decision builds on previous FDA approval for the drug’s treatment when combined with additional oral antidepressants. While Spravato’s underlying mechanisms remain unclear and only be ...
On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...